BXN Stock Overview
A life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bioxyne Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.021 |
| 52 Week Low | AU$0.004 |
| Beta | 0.78 |
| 11 Month Change | -28.57% |
| 3 Month Change | 100.00% |
| 1 Year Change | -16.67% |
| 33 Year Change | -56.52% |
| 5 Year Change | -47.37% |
| Change since IPO | -94.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXN | AU Personal Products | AU Market | |
|---|---|---|---|
| 7D | -23.1% | 2.7% | 0.2% |
| 1Y | -16.7% | 85.1% | 15.9% |
Return vs Industry: BXN underperformed the Australian Personal Products industry which returned 85.1% over the past year.
Return vs Market: BXN underperformed the Australian Market which returned 15.9% over the past year.
Price Volatility
| BXN volatility | |
|---|---|
| BXN Average Weekly Movement | 33.7% |
| Personal Products Industry Average Movement | 13.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: BXN's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BXN's weekly volatility has increased from 25% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Sam Watson | bioxyne.com |
Bioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products.
Bioxyne Limited Fundamentals Summary
| BXN fundamental statistics | |
|---|---|
| Market cap | AU$20.47m |
| Earnings (TTM) | -AU$12.80m |
| Revenue (TTM) | AU$9.64m |
2.1x
P/S Ratio-1.6x
P/E RatioIs BXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXN income statement (TTM) | |
|---|---|
| Revenue | AU$9.64m |
| Cost of Revenue | AU$5.93m |
| Gross Profit | AU$3.72m |
| Other Expenses | AU$16.51m |
| Earnings | -AU$12.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0063 |
| Gross Margin | 38.53% |
| Net Profit Margin | -132.73% |
| Debt/Equity Ratio | 1.1% |
How did BXN perform over the long term?
See historical performance and comparison